Prognostic relevance of the mTOR pathway in renal cell carcinoma
Author:
Publisher
Wiley
Subject
Cancer Research,Oncology
Reference47 articles.
1. Renal cell carcinoma
2. Cancer Statistics, 2006
3. Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma
4. Mathematical Model to Predict Individual Survival for Patients With Renal Cell Carcinoma
5. Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Cited by 304 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Analysis of HIF-1α expression and genetic polymorphisms in human clear cell renal cell carcinoma;Pathology and Oncology Research;2024-01-11
2. Computational analysis of protein–protein interactions of cancer drivers in renal cell carcinoma;FEBS Open Bio;2023-11-27
3. Prediction of Distant Metastases in Patients with Kidney Cancer Based on Gene Expression and Methylation Analysis;Diagnostics;2023-07-06
4. A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma;Human Vaccines & Immunotherapeutics;2023-06-30
5. Role of mammalian target of rapamycin (mTOR) signalling in oncogenesis;Life Sciences;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3